Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.47 |
| ▸ | LOX | P28300 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL778956 | 0.86 | PTGS2 (0.50) | PTGS2PTGS1FFAR4 | |
| SCHEMBL4616270 | 0.82 | ALDH1A1 (0.52) | PTGS2PTGS1FFAR4 | |
| SCHEMBL6262479 | 0.80 | PTGS2 (0.44) | PTGS2PTGS1 | |
| SCHEMBL3750244 | 0.78 | ABL1 (0.51) | PTGS2 | |
| SCHEMBL20408989 | 0.78 | ALDH1A1 (0.47) | PTGS2FFAR4 | |
| SCHEMBL8978705 | 0.76 | HSD11B1 (0.47) | FFAR4 | |
| SCHEMBL3758978 | 0.76 | GAA (0.46) | PTGS2PTGS1 | |
| SCHEMBL29639004 | 0.76 | PTGS2 (0.56) | PTGS2PTGS1 | |
| SCHEMBL27692347 | 0.75 | PTGS2 (0.58) | PTGS2PTGS1 | |
| SCHEMBL27887044 | 0.75 | ACHE (0.50) | PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6743787-B2 | FOR THERAPY OF METABOLIC DISORDERS MEDIATED BY INSULIN RESISTANCE OR HYPERGLYCEMIA IN A MAMMAL | WYETH | 2004-06-01 | — | — | US | disclosed |
| US-20030027795-A1 | N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists | WYETH | 2003-02-06 | — | — | US | disclosed |
| US-6444685-B1 | THERAPY FOR METABOLISM DISEASES; DIETETICS; ANTIDIABETIC AGENTS | WYETH | 2002-09-03 | — | — | US | disclosed |
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION | 2002-03-07 | — | — | US | disclosed |
| WO-2002006274-A1 | N-(4-SULFONYLARYL)CYCLYLAMINE-2-HYDROXYETHYLAMINES AS BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027795-A1 | N-(4-sulfonylaryl)cyclylamine-2-hydroxyethylamines as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | PTGS2 3905/4885PTGS1 3713/4885MAOA 2908/4885 |
| US-20020028797-A1 | N-(4-sulfonylaryl)Cyclylamine 2-hydroxyethylamines as beta-3 adrenergic receptor agonists | ADRB3, ADRB1, ADRB2 | PTGS2 3857/4885PTGS1 3649/4885MAOA 2448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.